Pacira BioSciences, Inc. (NASDAQ: PCRX) Stock Competitors & Peer Comparison
See PCRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PCRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PCRX | $25.76 | -0.27% | 1B | 9.91 | $2.60 | N/A |
| TAK | $18.03 | +0.00% | 57.4B | 12.97 | $1.39 | +3.50% |
| HLN | $10.11 | +0.70% | 44.5B | 18.85 | $0.54 | +1.23% |
| TEVA | $36.44 | -3.14% | 42.4B | 12.43 | $2.93 | N/A |
| ZTS | $77.34 | +3.09% | 32.4B | 11.75 | $6.58 | +2.70% |
| VTRS | $16.34 | -3.26% | 19B | 6.48 | $2.52 | +2.92% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.11 | -1.55% | 12B | 22.76 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.18 | +0.16% | 10.1B | 19.97 | $0.61 | +0.69% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
PCRX vs TAK Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TAK has a market cap of 57.4B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TAK trades at $18.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TAK's P/E ratio is 12.97. In terms of profitability, PCRX's ROE is +0.02%, compared to TAK's ROE of +0.02%. Regarding short-term risk, PCRX is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check TAK's competition here
Haleon plc (NYSE: HLN)
PCRX vs HLN Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while HLN trades at $10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas HLN's P/E ratio is 18.85. In terms of profitability, PCRX's ROE is +0.02%, compared to HLN's ROE of +0.17%. Regarding short-term risk, PCRX is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
PCRX vs TEVA Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TEVA has a market cap of 42.4B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TEVA trades at $36.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TEVA's P/E ratio is 12.43. In terms of profitability, PCRX's ROE is +0.02%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, PCRX is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
PCRX vs ZTS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ZTS trades at $77.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ZTS's P/E ratio is 11.75. In terms of profitability, PCRX's ROE is +0.02%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, PCRX is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
PCRX vs VTRS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while VTRS trades at $16.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas VTRS's P/E ratio is 6.48. In terms of profitability, PCRX's ROE is +0.02%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, PCRX is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
PCRX vs ITCI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ITCI's P/E ratio is -180.64. In terms of profitability, PCRX's ROE is +0.02%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, PCRX is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
PCRX vs ELAN Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ELAN has a market cap of 12B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ELAN trades at $24.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ELAN's P/E ratio is 22.76. In terms of profitability, PCRX's ROE is +0.02%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, PCRX is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
PCRX vs CTLT Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CTLT's P/E ratio is -27.84. In terms of profitability, PCRX's ROE is +0.02%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, PCRX is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
PCRX vs RDY Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while RDY trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas RDY's P/E ratio is 19.97. In terms of profitability, PCRX's ROE is +0.02%, compared to RDY's ROE of +0.09%. Regarding short-term risk, PCRX is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
PCRX vs ALKS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ALKS trades at $47.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ALKS's P/E ratio is 49.91. In terms of profitability, PCRX's ROE is +0.02%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, PCRX is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
PCRX vs LNTH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while LNTH trades at $100.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas LNTH's P/E ratio is 16.94. In terms of profitability, PCRX's ROE is +0.02%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, PCRX is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
PCRX vs AMRX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while AMRX trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas AMRX's P/E ratio is 19.49. In terms of profitability, PCRX's ROE is +0.02%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, PCRX is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
PCRX vs INDV Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while INDV trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas INDV's P/E ratio is 9.55. In terms of profitability, PCRX's ROE is +0.02%, compared to INDV's ROE of -2.16%. Regarding short-term risk, PCRX is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
PCRX vs ALVOW Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, PCRX's ROE is +0.02%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, PCRX is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
PCRX vs RGC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while RGC trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas RGC's P/E ratio is -387.32. In terms of profitability, PCRX's ROE is +0.02%, compared to RGC's ROE of -2.32%. Regarding short-term risk, PCRX is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
PCRX vs SUPN Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while SUPN trades at $43.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas SUPN's P/E ratio is 14.29. In terms of profitability, PCRX's ROE is +0.02%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, PCRX is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
PCRX vs BHC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while BHC trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas BHC's P/E ratio is 1.61. In terms of profitability, PCRX's ROE is +0.02%, compared to BHC's ROE of +0.89%. Regarding short-term risk, PCRX is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
PCRX vs DCPH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas DCPH's P/E ratio is -11.58. In terms of profitability, PCRX's ROE is +0.02%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, PCRX is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
PCRX vs HCM Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while HCM trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas HCM's P/E ratio is 4.64. In terms of profitability, PCRX's ROE is +0.02%, compared to HCM's ROE of +0.01%. Regarding short-term risk, PCRX is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
PCRX vs AVDL Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, PCRX's ROE is +0.02%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, PCRX is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
PCRX vs TRLV Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TRLV trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TRLV's P/E ratio is -4.80. In terms of profitability, PCRX's ROE is +0.02%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, PCRX is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
PCRX vs PRGO Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while PRGO trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas PRGO's P/E ratio is 5.80. In terms of profitability, PCRX's ROE is +0.02%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, PCRX is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
PCRX vs EMBCV Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas EMBCV's P/E ratio is N/A. In terms of profitability, PCRX's ROE is +0.02%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, PCRX is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
PCRX vs DVAX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas DVAX's P/E ratio is -41.89. In terms of profitability, PCRX's ROE is +0.02%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, PCRX is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
PCRX vs ALVO Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ALVO trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ALVO's P/E ratio is -14.56. In terms of profitability, PCRX's ROE is +0.02%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, PCRX is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ALVO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
PCRX vs ANIP Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ANIP trades at $72.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ANIP's P/E ratio is 8.86. In terms of profitability, PCRX's ROE is +0.02%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, PCRX is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
PCRX vs ETON Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ETON trades at $59.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ETON's P/E ratio is 129.96. In terms of profitability, PCRX's ROE is +0.02%, compared to ETON's ROE of +0.40%. Regarding short-term risk, PCRX is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
PCRX vs TARO Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TARO's P/E ratio is 30.05. In terms of profitability, PCRX's ROE is +0.02%, compared to TARO's ROE of +0.03%. Regarding short-term risk, PCRX is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
PCRX vs PAHC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while PAHC trades at $37.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas PAHC's P/E ratio is 12.86. In terms of profitability, PCRX's ROE is +0.02%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, PCRX is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
PCRX vs HROW Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while HROW trades at $37.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas HROW's P/E ratio is -37.65. In terms of profitability, PCRX's ROE is +0.02%, compared to HROW's ROE of -1.04%. Regarding short-term risk, PCRX is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
PCRX vs CRON Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CRON trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CRON's P/E ratio is 32.10. In terms of profitability, PCRX's ROE is +0.02%, compared to CRON's ROE of +0.06%. Regarding short-term risk, PCRX is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
PCRX vs AMPH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, AMPH has a market cap of 970.5M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while AMPH trades at $22.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas AMPH's P/E ratio is 7.51. In terms of profitability, PCRX's ROE is +0.02%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, PCRX is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
PCRX vs PETQ Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas PETQ's P/E ratio is 83.73. In terms of profitability, PCRX's ROE is +0.02%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, PCRX is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
PCRX vs COLL Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, COLL has a market cap of 822.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while COLL trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas COLL's P/E ratio is 3.18. In terms of profitability, PCRX's ROE is +0.02%, compared to COLL's ROE of +0.16%. Regarding short-term risk, PCRX is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check COLL's competition here
Glass House Brands Inc (NYSE: GLAS)
PCRX vs GLAS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, GLAS has a market cap of 768.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while GLAS trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas GLAS's P/E ratio is -17.73. In terms of profitability, PCRX's ROE is +0.02%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, PCRX is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check GLAS's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
PCRX vs IRWD Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, IRWD has a market cap of 698M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas IRWD's P/E ratio is 5.44. In terms of profitability, PCRX's ROE is +0.02%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, PCRX is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
PCRX vs EVO Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, EVO has a market cap of 678.5M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while EVO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas EVO's P/E ratio is -2.70. In terms of profitability, PCRX's ROE is +0.02%, compared to EVO's ROE of -0.27%. Regarding short-term risk, PCRX is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
PCRX vs AQST Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, AQST has a market cap of 629.8M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while AQST trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas AQST's P/E ratio is -7.72. In terms of profitability, PCRX's ROE is +0.02%, compared to AQST's ROE of +2.44%. Regarding short-term risk, PCRX is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
PCRX vs EOLS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, EOLS has a market cap of 584.8M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while EOLS trades at $8.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas EOLS's P/E ratio is -28.12. In terms of profitability, PCRX's ROE is +0.02%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, PCRX is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
PCRX vs BDSI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas BDSI's P/E ratio is 6.82. In terms of profitability, PCRX's ROE is +0.02%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, PCRX is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
PCRX vs TLRY Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TLRY has a market cap of 513.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TLRY trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TLRY's P/E ratio is -4.23. In terms of profitability, PCRX's ROE is +0.02%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, PCRX is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
PCRX vs KMDA Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, KMDA has a market cap of 476.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while KMDA trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas KMDA's P/E ratio is 21.74. In terms of profitability, PCRX's ROE is +0.02%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, PCRX is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
PCRX vs CGC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CGC has a market cap of 421.9M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CGC's P/E ratio is -0.60. In terms of profitability, PCRX's ROE is +0.02%, compared to CGC's ROE of -0.33%. Regarding short-term risk, PCRX is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
PCRX vs TKNO Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TKNO has a market cap of 381.7M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TKNO trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TKNO's P/E ratio is -22.97. In terms of profitability, PCRX's ROE is +0.02%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, PCRX is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
PCRX vs EBS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, EBS has a market cap of 305.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while EBS trades at $5.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas EBS's P/E ratio is 4.11. In terms of profitability, PCRX's ROE is +0.02%, compared to EBS's ROE of -0.36%. Regarding short-term risk, PCRX is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
PCRX vs ALIM Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ALIM's P/E ratio is 5.28. In terms of profitability, PCRX's ROE is +0.02%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, PCRX is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
PCRX vs LNDC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas LNDC's P/E ratio is -4.04. In terms of profitability, PCRX's ROE is +0.02%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, PCRX is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
PCRX vs ACB Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ACB has a market cap of 248.4M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ACB trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ACB's P/E ratio is -8.19. In terms of profitability, PCRX's ROE is +0.02%, compared to ACB's ROE of -0.21%. Regarding short-term risk, PCRX is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
PCRX vs TYHT Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TYHT's P/E ratio is -1.61. In terms of profitability, PCRX's ROE is +0.02%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, PCRX is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TYHT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
PCRX vs ORGO Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ORGO has a market cap of 223.9M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ORGO trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ORGO's P/E ratio is 58.00. In terms of profitability, PCRX's ROE is +0.02%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, PCRX is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ORGO's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
PCRX vs CRDL Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CRDL has a market cap of 223.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CRDL trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CRDL's P/E ratio is -7.73. In terms of profitability, PCRX's ROE is +0.02%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, PCRX is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
PCRX vs SIGA Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, SIGA has a market cap of 219.5M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while SIGA trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas SIGA's P/E ratio is 11.33. In terms of profitability, PCRX's ROE is +0.02%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, PCRX is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SIGA's competition here
Journey Medical Corporation (NASDAQ: DERM)
PCRX vs DERM Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, DERM has a market cap of 205.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while DERM trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas DERM's P/E ratio is -20.19. In terms of profitability, PCRX's ROE is +0.02%, compared to DERM's ROE of -0.20%. Regarding short-term risk, PCRX is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
PCRX vs REPH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas REPH's P/E ratio is -8.04. In terms of profitability, PCRX's ROE is +0.02%, compared to REPH's ROE of -0.22%. Regarding short-term risk, PCRX is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
PCRX vs OGI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, OGI has a market cap of 171M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while OGI trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas OGI's P/E ratio is 2.73. In terms of profitability, PCRX's ROE is +0.02%, compared to OGI's ROE of +0.21%. Regarding short-term risk, PCRX is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
PCRX vs LFCR Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, LFCR has a market cap of 170.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while LFCR trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas LFCR's P/E ratio is -4.24. In terms of profitability, PCRX's ROE is +0.02%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, PCRX is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
PCRX vs THTX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas THTX's P/E ratio is -28.83. In terms of profitability, PCRX's ROE is +0.02%, compared to THTX's ROE of +0.17%. Regarding short-term risk, PCRX is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
PCRX vs ASRT Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ASRT's P/E ratio is -7.10. In terms of profitability, PCRX's ROE is +0.02%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, PCRX is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
PCRX vs CPIX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CPIX has a market cap of 126.8M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CPIX trades at $8.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CPIX's P/E ratio is -21.15. In terms of profitability, PCRX's ROE is +0.02%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, PCRX is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CPIX's competition here
BGM Group Ltd. (NASDAQ: BGM)
PCRX vs BGM Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, BGM has a market cap of 122.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while BGM trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas BGM's P/E ratio is -1.11. In terms of profitability, PCRX's ROE is +0.02%, compared to BGM's ROE of -0.07%. Regarding short-term risk, PCRX is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check BGM's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
PCRX vs SCTL Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas SCTL's P/E ratio is -7.86. In terms of profitability, PCRX's ROE is +0.02%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, PCRX is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
PCRX vs PROC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas PROC's P/E ratio is 1.53. In terms of profitability, PCRX's ROE is +0.02%, compared to PROC's ROE of -2.22%. Regarding short-term risk, PCRX is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
PCRX vs OPTN Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas OPTN's P/E ratio is -4.42. In terms of profitability, PCRX's ROE is +0.02%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, PCRX is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
PCRX vs ZOM Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ZOM's P/E ratio is -1.62. In terms of profitability, PCRX's ROE is +0.02%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, PCRX is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
PCRX vs GRVI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas GRVI's P/E ratio is 26.05. In terms of profitability, PCRX's ROE is +0.02%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, PCRX is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
PCRX vs ZYBT Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ZYBT has a market cap of 82M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ZYBT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ZYBT's P/E ratio is -7.86. In terms of profitability, PCRX's ROE is +0.02%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, PCRX is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
PCRX vs ZYNE Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, PCRX's ROE is +0.02%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, PCRX is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ZYNE's competition here
InterCure Ltd. (NASDAQ: INCR)
PCRX vs INCR Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, INCR has a market cap of 68.5M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while INCR trades at $5.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas INCR's P/E ratio is -13.34. In terms of profitability, PCRX's ROE is +0.02%, compared to INCR's ROE of -0.09%. Regarding short-term risk, PCRX is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check INCR's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
PCRX vs SSIC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas SSIC's P/E ratio is 11.93. In terms of profitability, PCRX's ROE is +0.02%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, PCRX is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
PCRX vs TLPH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TLPH's P/E ratio is -3.87. In terms of profitability, PCRX's ROE is +0.02%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, PCRX is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
PCRX vs VLNS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas VLNS's P/E ratio is -1.03. In terms of profitability, PCRX's ROE is +0.02%, compared to VLNS's ROE of N/A. Regarding short-term risk, PCRX is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
PCRX vs DRRX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas DRRX's P/E ratio is -4.44. In terms of profitability, PCRX's ROE is +0.02%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, PCRX is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
PCRX vs JUPW Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas JUPW's P/E ratio is -2.41. In terms of profitability, PCRX's ROE is +0.02%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, PCRX is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
PCRX vs QLI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas QLI's P/E ratio is -4.92. In terms of profitability, PCRX's ROE is +0.02%, compared to QLI's ROE of -0.16%. Regarding short-term risk, PCRX is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
PCRX vs CPHI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CPHI has a market cap of 36.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CPHI trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CPHI's P/E ratio is -2.10. In terms of profitability, PCRX's ROE is +0.02%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, PCRX is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
PCRX vs RMTI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while RMTI trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas RMTI's P/E ratio is -6.10. In terms of profitability, PCRX's ROE is +0.02%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, PCRX is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
PCRX vs HEXO Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas HEXO's P/E ratio is -0.26. In terms of profitability, PCRX's ROE is +0.02%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, PCRX is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
PCRX vs TXMD Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, TXMD has a market cap of 25.7M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while TXMD trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas TXMD's P/E ratio is 113.09. In terms of profitability, PCRX's ROE is +0.02%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, PCRX is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
PCRX vs AYTU Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while AYTU trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas AYTU's P/E ratio is -1.17. In terms of profitability, PCRX's ROE is +0.02%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, PCRX is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
PCRX vs CYTH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CYTH's P/E ratio is -0.80. In terms of profitability, PCRX's ROE is +0.02%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, PCRX is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
PCRX vs EVOK Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas EVOK's P/E ratio is -7.97. In terms of profitability, PCRX's ROE is +0.02%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, PCRX is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
PCRX vs OPTH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, OPTH has a market cap of 15.9M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while OPTH trades at $4.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas OPTH's P/E ratio is -18.08. In terms of profitability, PCRX's ROE is +0.02%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, PCRX is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
PCRX vs ACRX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ACRX's P/E ratio is -0.31. In terms of profitability, PCRX's ROE is +0.02%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, PCRX is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
PCRX vs CABR Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, CABR has a market cap of 12.6M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while CABR trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas CABR's P/E ratio is -2.48. In terms of profitability, PCRX's ROE is +0.02%, compared to CABR's ROE of -3.28%. Regarding short-term risk, PCRX is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
PCRX vs AGRX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas AGRX's P/E ratio is -0.89. In terms of profitability, PCRX's ROE is +0.02%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, PCRX is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
PCRX vs NLTX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas NLTX's P/E ratio is -0.28. In terms of profitability, PCRX's ROE is +0.02%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, PCRX is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
PCRX vs LCI Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas LCI's P/E ratio is -0.04. In terms of profitability, PCRX's ROE is +0.02%, compared to LCI's ROE of +1.66%. Regarding short-term risk, PCRX is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
PCRX vs ADMP Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ADMP's P/E ratio is -0.08. In terms of profitability, PCRX's ROE is +0.02%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, PCRX is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
PCRX vs YCBD Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while YCBD trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas YCBD's P/E ratio is -1.25. In terms of profitability, PCRX's ROE is +0.02%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, PCRX is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
PCRX vs GELS Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, GELS has a market cap of 5.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas GELS's P/E ratio is -1.11. In terms of profitability, PCRX's ROE is +0.02%, compared to GELS's ROE of -0.25%. Regarding short-term risk, PCRX is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
PCRX vs MNK Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas MNK's P/E ratio is -0.44. In terms of profitability, PCRX's ROE is +0.02%, compared to MNK's ROE of -0.36%. Regarding short-term risk, PCRX is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
PCRX vs FLGC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas FLGC's P/E ratio is -0.19. In terms of profitability, PCRX's ROE is +0.02%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, PCRX is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
PCRX vs UPC Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while UPC trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas UPC's P/E ratio is -0.62. In terms of profitability, PCRX's ROE is +0.02%, compared to UPC's ROE of -0.03%. Regarding short-term risk, PCRX is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
PCRX vs SBFM Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while SBFM trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas SBFM's P/E ratio is -0.19. In terms of profitability, PCRX's ROE is +0.02%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, PCRX is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
PCRX vs PLXP Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas PLXP's P/E ratio is -0.22. In terms of profitability, PCRX's ROE is +0.02%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, PCRX is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
PCRX vs ATNX Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas ATNX's P/E ratio is -0.02. In terms of profitability, PCRX's ROE is +0.02%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, PCRX is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for PCRX.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
PCRX vs SNOA Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while SNOA trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas SNOA's P/E ratio is -1.11. In terms of profitability, PCRX's ROE is +0.02%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, PCRX is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
PCRX vs SHPH Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while SHPH trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas SHPH's P/E ratio is -0.17. In terms of profitability, PCRX's ROE is +0.02%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, PCRX is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check SHPH's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
PCRX vs RDHL Comparison September 2026
Pacira BioSciences, Inc. (NASDAQ: PCRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCRX stands at 1B. In comparison, RDHL has a market cap of 2.1M. Regarding current trading prices, PCRX is priced at $25.76 on the NASDAQ, while RDHL trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCRX currently has a P/E ratio of 9.91, whereas RDHL's P/E ratio is 0.13. In terms of profitability, PCRX's ROE is +0.02%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, PCRX is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for PCRX.Check RDHL's competition here